ClinicalTrials.gg
RecruitingNCT06256458ARTISTUpdated Nov 19, 2026

Prospective Registry to Evaluate Outcomes of NanoBone® Bone Graft in Acute Trauma

An observational study in Fractures, Bone, sponsored by Artoss Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Artoss Inc. · Observational

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 192 studies in Fractures, Bone with a site in United States — 37 open to participants now, 43 under way, 2 of them phase 3. Fractures, Bone · United States.

Planned enrollment
19th of 63
200 · median 100
Started
2023
with 6 others
Observational
63 of 192
17 open now
Primary completion
2026-12
later than 12 of 42 live
Registered
170th of 192
by date

Among the 192 studies in Fractures, Bone with a site in United States, this one is the 19th largest by planned enrollment of the 63 observational ones that give a count, is one of 7 that started in 2023, is one of 63 observational ones, reaches primary completion later than 12 of the 42 other live ones, and was the 170th registered.

Fractures, Bone

725 studies on the registry are indexed under Fractures, Bone; 116 are open to participants now.

Browse Fractures, Bone studies →

Open to participants now

37 of the 192 studies in Fractures, Bone with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 73 Fractures, Bone studies recruiting now, 36 (49%) set no upper age limit and 23 (32%) stop at 75 or younger; 18 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 192 studies in Fractures, Bone with a site in United States, or all of them as a file.
02

Study summary

This multicenter prospective patient registry was developed with the aim of documenting how orthopedic surgeons are utilizing the NanoBone products in acute trauma cases along with relevant patient outcomes. These outcomes include radiographic measures such as fracture healing, instrumentation integrity, and clinical outcomes (symptom and function improvement) based on investigator and patient-based outcome assessments.

Read the detailed description

This multicenter prospective patient registry was developed with the aim of documenting how orthopedic surgeons are utilizing the NanoBone products in acute trauma cases along with relevant patient outcomes. These outcomes include radiographic measures such as fracture healing, instrumentation integrity, and clinical outcomes (symptom and function improvement) based on investigator and patient-based outcome assessments.

The primary objective of this study is to document and analyze the use of NanoBone products in acute trauma cases (as a stand-alone bone graft, or in combination with local bone only, no other bone graft substitute or biologic product used) and determine both radiographic success and clinical outcomes. All product related adverse events will be documented, tabulated, and summarized.

03

Conditions studied

  • Fractures, Bone

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients in the study will be drawn from the individual surgeons' practice. Patients will be among those already surgically treated for trauma but have not completed their standard of care follow-up as determined by the surgeon's practice. In addition, the surgeon had determined that the use of a NanoBone product was clinically necessary for the patient. The choice of a NanoBone product was independent of this research project. Only patients who have had NanoBone implanted and consent to participate and meet the inclusion-exclusion criteria will be included in the registry.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects at least 18 years old at the time of injury
  2. Acute fractures, resulting from blunt or penetrating trauma

    • In the extremities or pelvis
    • Requiring surgery
    • Treated emergently, delayed or staged up to 4 weeks from the date of injury
    • Where bone grafting is clinically indicated

Exclusion criteria

Exclusion Criteria:

  1. Certain fracture locations (these apply to non-unions as well)

    • Hand - metacarpals, phalanges
    • Forefoot - metatarsals, phalanges
    • Skull
    • Spine
  2. Fractures requiring definitive fracture stabilization beyond the initial 4 weeks from the date of injury
  3. Pathologic fractures secondary to
  4. Subjects unable to follow recommended post-operative plan and complete follow ups
  5. Subjects unable to complete patient reported outcome measures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Interventions

  • DeviceNanoBone® Bone Graft

    The surgical technique used by the surgeon and the choice of the specific NanoBone product is or was determined solely by the surgeon and is independent of this observational study.

06

What researchers measure

Primary outcomes

  1. Radiographic evidence of fracture healing

    AP and lateral x-rays

    Time frame: 2 weeks, 6 weeks, 3 months, 6 months

Secondary outcomes

  1. Pain relief

    Visual Analog Scale (VAS) pain score at fracture site. 0-10 scale, lower score means less pain.

    Time frame: 2 weeks, 6 weeks, 3 months, 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.

Of 87 observational studies under Fractures, Bone, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 124. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2024
First posted
Feb 13, 2024
StartActual
Dec 1, 2023
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06256458
Lead sponsor
Artoss Inc.
Responsible party
Sponsor
First posted
Feb 13, 2024
Start date
Dec 1, 2023
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Nov 19, 2026

Study contacts

James J Cassidy, Ph.D.
Contact
jcassidy@artossinc.com
320-259-4321
Mitchell D Kuhl, DO
principal investigator · SSM Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion